Yudu - Nanotimes January 2011

11-01 :: December 2010 / January 2011

nanotimes

Companies Facts

olyplus-transfection SA, which specializes in the development of innovative solutions for the

delivery of nucleic acids in research and therapeu- tics, announced the completion of a funding round in which it raised EUR2.5 million. This new round brings in new shareholders in Polyplus-transfection, AIRFI (Alsace Inter Regio Fonds d’Investissement) and Sudinnova, which have invested EUR1 million and EUR0.5 million, respectively. Two of the company’s existing shareholders, CIC Vizille Capital Innovation and CIC Finance, also participated in this round. http://www.polyplus-transfection.com

Sivida Corp. (NASDAQ: PSDV, ASX:PVA) has entered into a securities purchase agreement

with institutional investors to raise gross proceeds of approximately $10.75 million in a registered direct offering through the sale of a total of 2,150,000 shares of the Company’s common stock and warrants to purchase 537,500 shares of its common stock. The net proceeds from the sale, after deducting place- ment agent fees and other estimated offering ex- penses, will be approximately $9.9 million. The com- mon stock and warrants will be sold in units, with each unit consisting of one share of common stock and the equivalent of a warrant to purchase 0.25 shares of common stock. Each purchaser will receive warrants to purchase a number of whole shares of common stock equal to 25% of the number of shares of common stock purchased by such purchaser. Each unit will be sold at a negotiated price of $5.00 per unit. Each warrant will be exercisable for one share of common stock, has an exercise price of $5.00 per share and will be exercisable for five years. These securities are being offered through an effective re- gistration statement.

pSivida is a world leader in the development of tiny drug delivery products that are administered by implantation, injection or insertion and provide sustained release of drugs on a controlled and level basis for months or years. The Company uses these systems to develop treatments for serious, unmet, medical needs. The Company‘s most advanced product candidate, Iluvien®

, delivers fluocinolone

acetonide (FA) for the treatment of diabetic macular edema.

http://www.psivida.com Q

inetiQ Group plc (LSE: QQ) has successfully completed the re-financing of its existing

credit facility, which matures in August 2012, with a new five-year revolving credit facility provided by the Group‘s six global, relationship banks. The new multi-currency facility, which matures in February 2016, totals £275m and will be un-drawn.

Leo Quinn, Chief Executive Officer of QinetiQ said: „The early re-financing of QinetiQ‘s credit facility demonstrates the improved strength of the Group‘s balance sheet and marks another important mile- stone in our self-help programme.“ http://www.qinetiq.com

S Carb®

iemens recently launched a new catalytic activated carbon under the company’s Aqua- liquid phase carbon family. AquaCarb®

1240CAT was developed for specific applications that require a catalytic reaction to remove the target contaminant. These applications include chlora- mine, hydrogen sulfide (H2S), and hydrogen pero- xide (H2

O2 based carbon, AquaCarb®

) removal from water. As a coconut shell 1240CAT offers all the

typical advantages in a coconut carbon, including a